Uncategorized
Intravitreal ranibizumab yields long-term improvements in diabetic retinopathy severity
Patients who received intravitreal ranibizumab treatment alone showed better improvement in diabetic retinopathy severity than patients receiving sham and intravitreal ranibizumab treatment, according to a study.The study analyzed the RISE and RIDE trials, which included 759 patients with diabetic macular edema (DME) randomized to receive 0.3 mg or 0.5 mg ranibizumab (Lucentis, Genentech), or sham injections.